近年來,
研究指出間充質幹細胞扮演著自我更新,
分化,
提高運輸蛋白的活
性並且有能力使癌症細胞產生轉移,
值得注意的是,
許多研究表明說骨髓間充質
幹細胞會移動到癌症腫瘤的周圍,
被認為是癌症轉移的重要微環境,
間充質幹細
胞不止影響了癌症細胞的自我更新跟分化,
並且會對於腫瘤幹細胞進行轉移。
我們利用系統生物學的方式來做進一步的探討,
根據MSCs-treated
microarray data 跟Control microarray data 我們可以建構出兩個不同的蛋白質之
間的交互網路, 並且透過兩個網路的差別, 找出間充質幹細胞在肺癌中所扮演的
重要角色, 在研究中我們發現了許多重要的腫瘤幹細胞的標記物以及Pathway 被
活化, 這些發現可以幫助我們對於未來的癌症治療有進一步的發展．

Background:
Evidence is emerging that stem cell and systems biology could provide new insights into the design of novel therapeutic strategies for cancer patients. Recent studies indicated that mesenchymal stem cells (MSCs) might play a crucial role in the ability of self-renewal, differentiation, increased membrane transporter activity and the ability to metastasize for cancer cells. It is worth noting that studies have shown that bone marrow-derived MSCs are recruited towards cancer tumors and are thought to be an important microenvironment in the initiation of metastasis. MSCs may not only promote the ability of self-renewal and differentiation of cancer cells, but also be involved in initiation of metastasis of cancer stem cells (CSCs).
Cancers are attributable to a large extent to multiple spontaneous and inherited mutations that control central cellular events. There are complicated cross-talks between pathways and biochemical processes that drive the formation and growth of tumors in cancers. As opposed to conventional biology, we apply a systems perspective into the cancerous cells, and systems biology approaches would help us explore how protein-protein interactions (PPIs) and pathways are induced and controlled during the initialization or formation of lung CSCs. In this study, our main goal is to investigate the complex intracellular mechanisms leading to the formation of lung CSCs. Specifically, we seek to study the crucial signaling pathways and possible cross-talks between these pathways that initiate the metastasis or formation of CSCs.
Result:
Based on MSCs-treated microarray data and Control microarray data, we constructed two intracellular PPI networks. The resulting intracellular MSCs-treated PPI network was comprised of 2586 proteins and 7296 interactions; on the other hand, the intracellular Control PPI network was comprised of 3982 proteins and 11498 interactions. By comparing these two networks, we could find out and predict the role
i
of the MSCs-secreted factors in the initialization or metastasis of lung CSCs. Our results showed that JAK/STAT pathway might play a crucial role in this setting. Furthermore, we identified STAT3 in our extracted sub-network and crucial proteins, CREBBP, FGFR2, CD44, and NFKB1, were also identified to be pertinent during lung CSCs formation via our centrality analysis.
Conclusion:
Based on our constructed PPI networks, pathway and centrality analysis, we were able to identify crucial proteins that are highly related to the formation of lung CSCs during treatment of MSCs-secreted factors. We believe that our findings not only provide insights into our comprehension of the formation of CSCs in lung cancers but also shed lights on our path towards better therapeutic strategies for cancer treatment in general.

[1] A. K. Templeton, S. Miyamoto, A. Babu, A. Munshi, and R. Ramesh, "Cancer stem cells: progress and challenges in lung cancer," Stem Cell Investigation, vol. 1, p. 9, 2014.
[2] S. A. Khuder, "Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis," Lung cancer, vol. 31, pp. 139-148, 2001.
[3] K. M. O’REILLY, A. M. Mclaughlin, W. S. Beckett, and P. J. Sime, "Asbestos-related lung disease," Chest, vol. 100, p. 2, 2007.
[4] U. D. o. Health and H. Services, "The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General," Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, vol. 709, 2006.
[5] W. H. Organization and I. A. f. R. o. Cancer, Tobacco smoke and involuntary smoking vol. 83: IARC, 2004.
[6] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, "Stem cells, cancer, and cancer stem cells," nature, vol. 414, pp. 105-111, 2001.
[7] C. Scheel and R. A. Weinberg, "Cancer stem cells and epithelial–mesenchymal transition: concepts and molecular links," in Seminars in cancer biology, 2012, pp. 396-403.
[8] S. Sell and G. B. Pierce, "Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers," Laboratory investigation; a journal of technical methods and pathology, vol. 70, pp. 6-22, 1994.
[9] D. R. Pattabiraman and R. A. Weinberg, "Tackling the cancer stem cells—what challenges do they pose?," Nature Reviews Drug Discovery, vol. 13, pp. 497-512, 2014.
[10] J. P. Thiery and J. P. Sleeman, "Complex networks orchestrate epithelial–mesenchymal transitions," Nature reviews Molecular cell biology, vol. 7, pp. 131-142, 2006.
[11] S. J. Morrison and A. C. Spradling, "Stem cells and niches: mechanisms that promote stem cell maintenance throughout life," Cell, vol. 132, pp. 598-611, 2008.
[12] C. E. Murry and G. Keller, "Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development," Cell, vol. 132, pp. 661-680, 2008.
[13] C. L. Sawyers, C. T. Denny, and O. N. Witte, "Leukemia and the disruption of normal hematopoiesis," Cell, vol. 64, pp. 337-350, 1991.
[14] C. A. Klein, "Gene expression signatures, cancer cell evolution and metastatic progression," Cell Cycle, vol. 3, pp. 28-30, 2004.
[15] P. Covitz, "Class struggle: expression profiling and categorizing cancer," PHARMACOGENOMICS JOURNAL, vol. 3, pp. 257-260, 2003.
[16] D. Hanahan and R. A. Weinberg, "The hallmarks of cancer," cell, vol. 100, pp. 57-70, 2000.
[17] J. J. Hornberg, F. J. Bruggeman, H. V. Westerhoff, and J. Lankelma, "Cancer: a systems biology disease," Biosystems, vol. 83, pp. 81-90, 2006.
[18] B. D. MacArthur, A. Ma'ayan, and I. R. Lemischka, "Systems biology of stem cell fate and cellular reprogramming," Nature Reviews Molecular Cell Biology, vol. 10, pp. 672-681, 2009.
[19] L. Hood, J. R. Heath, M. E. Phelps, and B. Lin, "Systems biology and new technologies enable predictive and preventative medicine," Science, vol. 306, pp. 640-643, 2004.
[20] G. Östlund, M. Lindskog, and E. L. Sonnhammer, "Network-based Identification of novel cancer genes," Molecular & Cellular Proteomics, vol. 9, pp. 648-655, 2010.
[21] T. Milenković, V. Memišević, A. K. Ganesan, and N. Pržulj, "Systems-level cancer gene identification from protein interaction network topology applied to melanogenesis-related functional genomics data," Journal of The Royal Society Interface, vol. 7, pp. 423-437, 2010.
[22] O. Dakhova, M. Ozen, C. J. Creighton, R. Li, G. Ayala, D. Rowley, et al., "Global gene expression analysis of reactive stroma in prostate cancer," Clinical Cancer Research, vol. 15, pp. 3979-3989, 2009.
[23] C. Stark, B.-J. Breitkreutz, T. Reguly, L. Boucher, A. Breitkreutz, and M. Tyers, "BioGRID: a general repository for interaction datasets," Nucleic acids research, vol. 34, pp. D535-D539, 2006.
[24] Y.-C. Wang and B.-S. Chen, "Integrated cellular network of transcription regulations and protein-protein interactions," BMC Systems Biology, vol. 4, p. 20, 2010.
[25] H. Akaike, "A new look at the statistical model identification," Automatic Control, IEEE Transactions on, vol. 19, pp. 716-723, 1974.
[26] Y. Sakamoto, M. Ishiguro, and G. Kitagawa, "Akaike information criterion statistics," Dordrecht, The Netherlands: D. Reidel, 1986.
[27] V. Tirino, R. Camerlingo, R. Franco, D. Malanga, A. La Rocca, G. Viglietto, et al., "The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer," European Journal of Cardio-Thoracic Surgery, vol. 36, pp. 446-453, 2009.
[28] E. L.-H. Leung, R. R. Fiscus, J. W. Tung, V. P.-C. Tin, L. C. Cheng, A. Sihoe, et al., "Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties," PloS one, vol. 5, p. e14062, 2010.
[29] S. Singh, J. Trevino, N. Bora-Singhal, D. Coppola, E. Haura, S. Altiok, et al., "EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer," Mol Cancer, vol. 11, p. 73, 2012.
[30] J. Kim, J. Chu, X. Shen, J. Wang, and S. H. Orkin, "An extended transcriptional network for pluripotency of embryonic stem cells," Cell, vol. 132, pp. 1049-1061, 2008.
[31] M. Schoenhals, A. Kassambara, J. De Vos, D. Hose, J. Moreaux, and B. Klein, "Embryonic stem cell markers expression in cancers," Biochemical and biophysical research communications, vol. 383, pp. 157-162, 2009.
[32] S.-H. Chiou, M.-L. Wang, Y.-T. Chou, C.-J. Chen, C.-F. Hong, W.-J. Hsieh, et al., "Coexpression of Oct4 and Nanog Enhances Malignancy in Lung Adenocarcinoma by Inducing Cancer Stem Cell–Like Properties and Epithelial–Mesenchymal Transdifferentiation," Cancer research, vol. 70, pp. 10433-10444, 2010.
[33] M. Dean, T. Fojo, and S. Bates, "Tumour stem cells and drug resistance," Nature Reviews Cancer, vol. 5, pp. 275-284, 2005.
[34] J. I. Fletcher, M. Haber, M. J. Henderson, and M. D. Norris, "ABC transporters in cancer: more than just drug efflux pumps," Nature Reviews Cancer, vol. 10, pp. 147-156, 2010.
[35] G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, "Targeting multidrug resistance in cancer," Nature reviews Drug discovery, vol. 5, pp. 219-234, 2006.
[36] E. Teodori, S. Dei, C. Martelli, S. Scapecchi, and F. Gualtieri, "The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR)," Current drug targets, vol. 7, pp. 893-909, 2006.
[37] M.-H. Yang, D. S.-S. Hsu, H.-W. Wang, H.-J. Wang, H.-Y. Lan, W.-H. Yang, et al., "Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition," Nature Cell Biology, vol. 12, pp. 982-992, 2010.
[38] A. Cano, M. A. Pérez-Moreno, I. Rodrigo, A. Locascio, M. J. Blanco, M. G. del Barrio, et al., "The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression," Nature cell biology, vol. 2, pp. 76-83, 2000.
[39] A. Satelli and S. Li, "Vimentin in cancer and its potential as a molecular target for cancer therapy," Cellular and Molecular Life Sciences, vol. 68, pp. 3033-3046, 2011.
[40] Z. Yang, X. Zhang, H. Gang, X. Li, Z. Li, T. Wang, et al., "Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression," Biochemical and biophysical research communications, vol. 358, pp. 925-930, 2007.
[41] T. Opsahl, F. Agneessens, and J. Skvoretz, "Node centrality in weighted networks: Generalizing degree and shortest paths," Social Networks, vol. 32, pp. 245-251, 2010.
[42] U. Brandes, "A faster algorithm for betweenness centrality*," Journal of Mathematical Sociology, vol. 25, pp. 163-177, 2001.
[43] A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio, et al., "Identification and expansion of the tumorigenic lung cancer stem cell population," Cell Death & Differentiation, vol. 15, pp. 504-514, 2008.
[44] A. R. Campos and K. White, "Mutant alleles at the locus elav in Drosophila melanogaster lead to nervous system defects. A developmental-genetic analysis," Journal of neurogenetics, vol. 2, pp. 197-218, 1985.
[45] J. Dalmau, H. Furneaux, C. Cordon-Cardo, and J. Posner, "The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues," The American journal of pathology, vol. 141, p. 881, 1992.
[46] P. H. King, "Differential expression of the neuroendocrine genes Hel‐N1 and HuD in small‐cell lung carcinoma: Evidence for down‐regulation of HuD in the variant phenotype," International journal of cancer, vol. 74, pp. 378-382, 1997.
[47] P. H. King and E. J. Dropcho, "Expression of Hel‐N1 and HeL‐N2 in small‐cell lung carcinoma," Annals of neurology, vol. 39, pp. 679-681, 1996.
[48] R. I. Nicholson, J. M. W. Gee, and M. E. Harper, "EGFR and cancer prognosis," European Journal of Cancer, vol. 37, pp. 9-15, 2001.
[49] V. I. Rebel, A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson, and D. M. Livingston, "Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal," Proceedings of the National Academy of Sciences, vol. 99, pp. 14789-14794, 2002.
[50] T.-x. Xie, D. Wei, M. Liu, A. C. Gao, F. Ali-Osman, R. Sawaya, et al., "Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis," Oncogene, vol. 23, pp. 3550-3560, 2004.
[51] C. Huang, G. Yang, T. Jiang, G. Zhu, H. Li, and Z. Qiu, "The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro," Neoplasma, vol. 58, pp. 396-405, 2010.
[52] K.-W. Seo, K.-H. Roh, D. R. Bhandari, S.-B. Park, S.-K. Lee, and K.-S. Kang, "ZNF281 knockdown induced osteogenic differentiation of human multipotent stem cells in vivo and in vitro," Cell transplantation, vol. 22, pp. 29-40, 2013.
[53] G. Szakács, J.-P. Annereau, S. Lababidi, U. Shankavaram, A. Arciello, K. J. Bussey, et al., "Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells," Cancer cell, vol. 6, pp. 129-137, 2004.
[54] A. Petitjean, M. Achatz, A. Borresen-Dale, P. Hainaut, and M. Olivier, "TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes," Oncogene, vol. 26, pp. 2157-2165, 2007.
[55] A. Petitjean, E. Mathe, S. Kato, C. Ishioka, S. V. Tavtigian, P. Hainaut, et al., "Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database," Human mutation, vol. 28, pp. 622-629, 2007.
[56] T.-P. Yao, S. P. Oh, M. Fuchs, N.-D. Zhou, L.-E. Ch'ng, D. Newsome, et al., "Gene dosage–dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300," Cell, vol. 93, pp. 361-372, 1998.
[57] H. Kawasaki, R. Eckner, T.-P. Yao, K. Taira, R. Chiu, D. M. Livingston, et al., "Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation," Nature, vol. 393, pp. 284-289, 1998.
[58] R. B. Irby and T. J. Yeatman, "Role of Src expression and activation in human cancer," Oncogene, vol. 19, pp. 5636-5642, 2000.
[59] D. Shook and R. Keller, "Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development," Mechanisms of development, vol. 120, pp. 1351-1383, 2003.
[60] M. A. Nieto, "The ins and outs of the epithelial to mesenchymal transition in health and disease," Annual review of cell and developmental biology, vol. 27, pp. 347-376, 2011.
[61] D. G. Phinney and D. J. Prockop, "Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views," Stem cells, vol. 25, pp. 2896-2902, 2007.
[62] N. Turner and R. Grose, "Fibroblast growth factor signalling: from development to cancer," Nature Reviews Cancer, vol. 10, pp. 116-129, 2010.
[63] M. Karin, "Nuclear factor-κB in cancer development and progression," Nature, vol. 441, pp. 431-436, 2006.
[64] R. Escarcega, S. Fuentes-Alexandro, M. Garcia-Carrasco, A. Gatica, and A. Zamora, "The transcription factor nuclear factor-kappa B and cancer," Clinical oncology, vol. 19, pp. 154-161, 2007.
[65] J. Yang, J. R. Aguila, Z. Alipio, R. Lai, L. M. Fink, and Y. Ma, "Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4," J Hematol Oncol, vol. 4, pp. 38-38, 2011.
[66] N. Shah, B. Pang, K.-G. Yeoh, S. Thorn, C. S. Chen, M. B. Lilly, et al., "Potential roles for the PIM1 kinase in human cancer–a molecular and therapeutic appraisal," European Journal of Cancer, vol. 44, pp. 2144-2151, 2008.